{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:26:40Z","timestamp":1787372800298,"version":"build-2736575974"},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7369-26","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:10:53Z","timestamp":1787091053000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment"],"prefix":"10.2169","author":[{"given":"Saki","family":"Sueda","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Kawaoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatsue","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Nelson","family":"Hayes","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Tsuge","sequence":"additional","affiliation":[{"name":"Liver Center, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hiroshima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 69: 182-236, 2018."},{"key":"2","unstructured":"2. Group formed to establish \u201cGuidelines for evidence-based clinical practice for the treatment of liver cancer\u201d; Japan Society of Hepatology. Clinical practice guidelines for hepatocellular carcinoma (2021 version). Kanehara, Tokyo, Japan, 2021 (in Japanese)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389: 2492-2502, 2017.","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res 22: 1865-1874, 2016.","DOI":"10.1158\/1078-0432.CCR-15-1507"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wang L, Geng H, Liu Y, et al. Hot and cold tumors: immunological features and therapeutic strategies. MedComm 4: e343, 2023.","DOI":"10.1002\/mco2.343"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wu B, Zhang B, Li B, et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther 9: 274, 2024.","DOI":"10.1038\/s41392-024-01979-x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chen Y, Dai S, Cheng CS, et al. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. J Hematol Oncol 17: 130, 2024.","DOI":"10.1186\/s13045-024-01647-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamauchi M, Ono A, Amioka K, et al. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma. Commun Med (Lond) 3: 152, 2023.","DOI":"10.1038\/s43856-023-00390-x"},{"key":"9","unstructured":"9. World Health Organization, International Agency for Research on Cancer. GLOBOCAN 2022: Liver cancer fact sheet [Internet]. Available from: https:\/\/gco.iarc.fr\/"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382: 1894-1905, 2020.","DOI":"10.1056\/NEJMoa1915745"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1: e2200074, 2022.","DOI":"10.1056\/EVIDoa2100070"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tang H, Wang Y, Chlewicki LK, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29: 285-296, 2016.","DOI":"10.1016\/j.ccell.2016.02.004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Gyanchandani R, Ortega Alves MV, Myers JN, et al. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma. Mol Cancer Res 11: 1585-1596, 2013.","DOI":"10.1158\/1541-7786.MCR-13-0358"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gocher AM, Workman CJ, Vignali DAA. Interferon-\u03b3: teammate or opponent in the tumour microenvironment? Nat Rev Immunol 22: 158-172, 2022.","DOI":"10.1038\/s41577-021-00566-3"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Adachi Y, Kamiyama H, Ichikawa K, et al. Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. Cancer Res 82: 292-306, 2022.","DOI":"10.1158\/0008-5472.CAN-20-2426"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 17: 559-572, 2017.","DOI":"10.1038\/nri.2017.49"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Mei Z, Gao X, Pan C, et al. Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1<sup>+<\/sup> CD8<sup>+<\/sup> T cells in hepatocellular carcinoma via blocking VEGFR2. Cancer Sci 114: 1284-1296, 2023.","DOI":"10.1111\/cas.15719"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yamada T, Fujiwara N, Kubota N, et al. Lenvatinib recruits cytotoxic GZMK<sup>+<\/sup>CD8<sup>+<\/sup> T cells in hepatocellular carcinoma. Hepatol Commun 7: e0209, 2023.","DOI":"10.1097\/HC9.0000000000000209"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18: e143-e152, 2017.","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Wee MEU, Hung CH, Tsai MC, et al. Pseudoprogression in hepatocellular carcinoma during atezolizumab plus bevacizumab therapy: a case report and a review of literature. Cureus 17: e86905, 2025.","DOI":"10.7759\/cureus.86905"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264, 2012.","DOI":"10.1038\/nrc3239"},{"key":"22","unstructured":"22. Hsieh CH, Lin YH, Huang YH, et al. Immune checkpoint biology in hepatocellular carcinoma: mechanisms and roles in the tumor microenvironment. Oncol Lett 29: 15322, 2025."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Morihara H, Sakamoto T, Yamada R, et al. Anti-CTLA-4 treatment suppresses hepatocellular carcinoma growth through Th1-mediated cell cycle arrest and apoptosis. PLoS One 19: e0305984, 2024.","DOI":"10.1371\/journal.pone.0305984"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kawamura Y, Akuta N, Fujiyama S, et al. Two cases of advanced hepatocellular carcinoma who responded well to the combination of durvalumab plus tremelimumab after disease progression during atezolizumab plus bevacizumab therapy under bevacizumab withdrawal. Cureus 15: e45377, 2023.","DOI":"10.7759\/cureus.45385"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8: 1069-1086, 2018.","DOI":"10.1158\/2159-8290.CD-18-0367"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7369-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:10:48Z","timestamp":1787371848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7369-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7369-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7369-26"}}